Suzhou Alphamab Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Holding
- Established
- 2008-11-06
- Employees
- -
- Market Cap
- -
- Website
- http://www.alphamab.com
Clinical Trials
7
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT06747416
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors
- Conditions
- Hemophilia A Without InhibitorHemophilia B Without Inhibitor
- Interventions
- First Posted Date
- 2024-08-23
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 111
- Registration Number
- NCT06569108
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06547775
- Locations
- 🇨🇳
The Third Xiangya Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors
- Conditions
- Hemophilia B With InhibitorHemophilia A With Inhibitor
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 51
- Registration Number
- NCT06312475
- Locations
- 🇨🇳
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty
- Conditions
- Knee Arthroplasty, Total
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2023-12-29
- Lead Sponsor
- Suzhou Alphamab Co., Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06180889
- Locations
- 🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- Next
News
Diabetes Pipeline Shows Robust Growth with 200+ Companies Developing Novel Therapies
DelveInsight's 2025 report reveals over 200 companies are actively developing more than 200 pipeline therapies for diabetes treatment, indicating a highly competitive and innovative landscape.